Search Results - "Hammerman, Peter S"

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer by Dutt, Amit, Ramos, Alex H, Hammerman, Peter S, Mermel, Craig, Cho, Jeonghee, Sharifnia, Tanaz, Chande, Ajit, Tanaka, Kumiko Elisa, Stransky, Nicolas, Greulich, Heidi, Gray, Nathanael S, Meyerson, Matthew

“…Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are…”
Get full text

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application by Chae, Young Kwang, Ranganath, Keerthi, Hammerman, Peter S, Vaklavas, Christos, Mohindra, Nisha, Kalyan, Aparna, Matsangou, Maria, Costa, Ricardo, Carneiro, Benedito, Villaflor, Victoria M, Cristofanilli, Massimo, Giles, Francis J

“…The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase signaling pathway that has a fundamental role in many biologic…”
Get full text

Genomic analysis of metastatic cutaneous squamous cell carcinoma by Li, Yvonne Y, Hanna, Glenn J, Laga, Alvaro C, Haddad, Robert I, Lorch, Jochen H, Hammerman, Peter S

“…A rare 5% of cutaneous squamous cell carcinomas (cSCC) metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent…”
Get full text

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer by Raoof, Sana, Mulford, Iain J., Frisco-Cabanos, Heidie, Nangia, Varuna, Timonina, Daria, Labrot, Emma, Hafeez, Nafeeza, Bilton, Samantha J., Drier, Yotam, Ji, Fei, Greenberg, Max, Williams, August, Kattermann, Krystina, Damon, Leah, Sovath, Sosathya, Rakiec, Daniel P., Korn, Joshua M., Ruddy, David A., Benes, Cyril H., Hammerman, Peter S., Piotrowska, Zofia, Sequist, Lecia V., Niederst, Matthew J., Barretina, Jordi, Engelman, Jeffrey A., Hata, Aaron N.

“…Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major clinical challenge. In epidermal growth factor receptor ( EGFR )…”
Get full text

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas by Seiwert, Tanguy Y, Zuo, Zhixiang, Keck, Michaela K, Khattri, Arun, Pedamallu, Chandra S, Stricker, Thomas, Brown, Christopher, Pugh, Trevor J, Stojanov, Petar, Cho, Juok, Lawrence, Michael S, Getz, Gad, Brägelmann, Johannes, DeBoer, Rebecca, Weichselbaum, Ralph R, Langerman, Alexander, Portugal, Louis, Blair, Elizabeth, Stenson, Kerstin, Lingen, Mark W, Cohen, Ezra E W, Vokes, Everett E, White, Kevin P, Hammerman, Peter S

“…The genetic differences between human papilloma virus (HPV)-positive and -negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To…”
Get full text

Squamous cell lung cancer: from tumor genomics to cancer therapeutics by Gandara, David R, Hammerman, Peter S, Sos, Martin L, Lara, Jr, Primo N, Hirsch, Fred R

“…Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the past several years, therapeutic progress in SCC has lagged…”
Get full text

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung Adenocarcinoma by Li, Fei, Huang, Qingyuan, Luster, Troy A, Hu, Hai, Zhang, Hua, Ng, Wai-Lung, Khodadadi-Jamayran, Alireza, Wang, Wei, Chen, Ting, Deng, Jiehui, Ranieri, Michela, Fang, Zhaoyuan, Pyon, Val, Dowling, Catríona M, Bagdatlioglu, Ece, Almonte, Christina, Labbe, Kristen, Silver, Heather, Rabin, Alexandra R, Jani, Kandarp, Tsirigos, Aristotelis, Papagiannakopoulos, Thales, Hammerman, Peter S, Velcheti, Vamsidhar, Freeman, Gordon J, Qi, Jun, Miller, George, Wong, Kwok-Kin

“…Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with -mutant lung adenocarcinoma (LUAD) remains low. Combining…”
Get more information

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression by Xu, Chunxiao, Fillmore, Christine M., Koyama, Shohei, Wu, Hongbo, Zhao, Yanqiu, Chen, Zhao, Herter-Sprie, Grit S., Akbay, Esra A., Tchaicha, Jeremy H., Altabef, Abigail, Reibel, Jacob B., Walton, Zandra, Ji, Hongbin, Watanabe, Hideo, Jänne, Pasi A., Castrillon, Diego H., Rustgi, Anil K., Bass, Adam J., Freeman, Gordon J., Padera, Robert F., Dranoff, Glenn, Hammerman, Peter S., Kim, Carla F., Wong, Kwok-Kin

“…Lung squamous cell carcinoma (SCC) is a deadly disease for which current treatments are inadequate. We demonstrate that biallelic inactivation of Lkb1 and Pten…”
Get full text

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations by Li, Yvonne Y, Chung, Grace T. Y., Lui, Vivian W. Y., To, Ka-Fai, Ma, Brigette B. Y., Chow, Chit, Woo, John K, S., Yip, Kevin Y., Seo, Jeongsun, Hui, Edwin P., Mak, Michael K. F., Rusan, Maria, Chau, Nicole G., Or, Yvonne Y. Y., Law, Marcus H. N., Law, Peggy P. Y., Liu, Zoey W. Y., Ngan, Hoi-Lam, Hau, Pok-Man, Verhoeft, Krista R., Poon, Peony H. Y., Yoo, Seong-Keun, Shin, Jong-Yeon, Lee, Sau-Dan, Lun, Samantha W. M., Jia, Lin, Chan, Anthony W. H., Chan, Jason Y. K., Lai, Paul B. S., Fung, Choi-Yi, Hung, Suet-Ting, Wang, Lin, Chang, Ann Margaret V., Chiosea, Simion I., Hedberg, Matthew L., Tsao, Sai-Wah, van Hasselt, Andrew C., Chan, Anthony T. C., Grandis, Jennifer R., Hammerman, Peter S., Lo, Kwok-Wai

“…Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The…”
Get full text

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade by Akbay, Esra A, Koyama, Shohei, Liu, Yan, Dries, Ruben, Bufe, Lauren E, Silkes, Michael, Alam, Md Maksudul, Magee, Dillon M, Jones, Robert, Jinushi, Masahisa, Kulkarni, Meghana, Carretero, Julian, Wang, Xiaoen, Warner-Hatten, Tiquella, Cavanaugh, Jillian D, Osa, Akio, Kumanogoh, Atsushi, Freeman, Gordon J, Awad, Mark M, Christiani, David C, Bueno, Raphael, Hammerman, Peter S, Dranoff, Glenn, Wong, Kwok-Kin

“…Proinflammatory cytokine interleukin-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a…”
Get more information

A genetic basis for the variation in the vulnerability of cancer to DNA damage by Yard, Brian D., Adams, Drew J., Chie, Eui Kyu, Tamayo, Pablo, Battaglia, Jessica S., Gopal, Priyanka, Rogacki, Kevin, Pearson, Bradley E., Phillips, James, Raymond, Daniel P., Pennell, Nathan A., Almeida, Francisco, Cheah, Jaime H., Clemons, Paul A., Shamji, Alykhan, Peacock, Craig D., Schreiber, Stuart L., Hammerman, Peter S., Abazeed, Mohamed E.

“…Radiotherapy is not currently informed by the genetic composition of an individual patient’s tumour. To identify genetic features regulating survival after DNA…”
Get full text

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors by Tan, Li, Wang, Jun, Tanizaki, Junko, Huang, Zhifeng, Aref, Amir R, Rusan, Maria, Zhu, Su-Jie, Zhang, Yiyun, Ercan, Dalia, Liao, Rachel G, Capelletti, Marzia, Zhou, Wenjun, Hur, Wooyoung, Kim, NamDoo, Sim, Taebo, Gaudet, Suzanne, Barbie, David A, Yeh, Jing-Ruey Joanna, Yun, Cai-Hong, Hammerman, Peter S, Mohammadi, Moosa, Jänne, Pasi A, Gray, Nathanael S

“…The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation…”
Get full text

ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors by Terai, Hideki, Kitajima, Shunsuke, Potter, Danielle S, Matsui, Yusuke, Quiceno, Laura Gutierrez, Chen, Ting, Kim, Tae-Jung, Rusan, Maria, Thai, Tran C, Piccioni, Federica, Donovan, Katherine A, Kwiatkowski, Nicholas, Hinohara, Kunihiko, Wei, Guo, Gray, Nathanael S, Fischer, Eric S, Wong, Kwok-Kin, Shimamura, Teppei, Letai, Anthony, Hammerman, Peter S, Barbie, David A

“…An increasingly recognized component of resistance to tyrosine kinase inhibitors (TKI) involves persistence of a drug-tolerant subpopulation of cancer cells…”
Get full text

Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes by Zhang, Li, MacIsaac, Kenzie D, Zhou, Ting, Huang, Pei-Yu, Xin, Chunlin, Dobson, Jason R, Yu, Kun, Chiang, Derek Y, Fan, Yue, Pelletier, Marc, Wang, Yan, Jaeger, Savina, Krishnamurthy Radhakrishnan, Viveksagar, JeBailey, Lellean, Skewes-Cox, Peter, Zhang, Jing, Fang, Wenfeng, Huang, Yan, Zhao, Hongyun, Zhao, Yuanyuan, Li, En, Peng, Bin, Huang, Alan, Dranoff, Glenn, Hammerman, Peter S, Engelman, Jeffrey, Bitter, Hans, Zeng, Yi-Xin, Yao, Yao

“…Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated cancer characterized by a poor prognosis and a high level of lymphocyte infiltrate…”
Get full text

Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma by LIAO, Rachel G, JUNG, Joonil, GRAY, Nathanael S, GETZ, Gad, WONG, Kwok-Kin, HADDAD, Robert I, MEYERSON, Matthew, HAMMERMAN, Peter S, TCHAICHA, Jeremy, WILKERSON, Matthew D, SIVACHENKO, Andrey, BEAUCHAMP, Ellen M, QINGSONG LIU, PUGH, Trevor J, PEDAMALLUL, Chandra Sekhar, HAYES, D. Neil

“…A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung SCC) has recently been reported, enabling the identification of…”
Get full text

Therapeutic insights from genomic studies of head and neck squamous cell carcinomas by Hammerman, Peter S, Hayes, D Neil, Grandis, Jennifer R

“…Large and comprehensive genomic surveys of head and neck squamous cell carcinomas (HNSCC) are now greatly increasing our understanding of the diversity of this…”
Get more information

Identification and characterization of an alternative cancer-derived PD-L1 splice variant by Hassounah, Nadia B., Malladi, Venkat S., Huang, Yi, Freeman, Samuel S., Beauchamp, Ellen M., Koyama, Shohei, Souders, Nicholas, Martin, Sunil, Dranoff, Glenn, Wong, Kwok-Kin, Pedamallu, Chandra S., Hammerman, Peter S., Akbay, Esra A.

“…Therapeutic blockade of the PD-1/PD-L1 axis is recognized as an effective treatment for numerous cancer types. However, only a subset of patients respond to…”
Get full text

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors by Gao, Yang, Zhang, Tinghu, Terai, Hideki, Ficarro, Scott B, Kwiatkowski, Nicholas, Hao, Ming-Feng, Sharma, Bandana, Christensen, Camilla L, Chipumuro, Edmond, Wong, Kwok-Kin, Marto, Jarrod A, Hammerman, Peter S, Gray, Nathanael S, George, Rani E

“…Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription;…”
Get more information

Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients by Osa, Akio, Uenami, Takeshi, Koyama, Shohei, Fujimoto, Kosuke, Okuzaki, Daisuke, Takimoto, Takayuki, Hirata, Haruhiko, Yano, Yukihiro, Yokota, Soichiro, Kinehara, Yuhei, Naito, Yujiro, Otsuka, Tomoyuki, Kanazu, Masaki, Kuroyama, Muneyoshi, Hamaguchi, Masanari, Koba, Taro, Futami, Yu, Ishijima, Mikako, Suga, Yasuhiko, Akazawa, Yuki, Machiyama, Hirotomo, Iwahori, Kota, Takamatsu, Hyota, Nagatomo, Izumi, Takeda, Yoshito, Kida, Hiroshi, Akbay, Esra A, Hammerman, Peter S, Wong, Kwok-Kin, Dranoff, Glenn, Mori, Masahide, Kijima, Takashi, Kumanogoh, Atsushi

“…The PD-1-blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated the maximum…”
Get full text

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer by Sridharan, Vishwajith, Margalit, Danielle N, Lynch, Stephanie A, Severgnini, Mariano, Zhou, Jun, Chau, Nicole G, Rabinowits, Guilherme, Lorch, Jochen H, Hammerman, Peter S, Hodi, F Stephen, Haddad, Robert I, Tishler, Roy B, Schoenfeld, Jonathan D

“…Background: Preclinical and clinical studies suggest potential synergy between high dose per fraction focal radiation and immunotherapy. However,…”
Get full text